J Periodont Res 2010; 45: 292–295 All rights reserved

Short communication

Co-purified gelatinases alter the stability and biological activities of human plasma fibronectin preparations

Pal S, Chen Z, Xu X, Mikhailova M, Steffensen B. Co-purified gelatinases alter the stability and biological activities of human plasma fibronectin preparations. J Periodont Res 2010; 45: 292–295. © 2009 The Authors. Journal compilation © 2009 Blackwell Munksgaard

Background and Objective: Fibronectin (FN) is an important cell adhesion molecule that is used widely to characterize cell behavior. Preparations of FN purified from human plasma by gelatin–Sepharose affinity chromatography typically also contain gelatin-binding gelatinases that may cleave FN, reduce its stability and alter its biological activities. Available methods for separating gelatinases from FN are resource demanding. Therefore, our objective was to devise a time- and cost-efficient protocol for purification of gelatinase-free FN.

Material and Methods: Experiments tested the elution profiles for FN and gelatinases from gelatin–Sepharose using a concentration range (1–7%) of dimethyl sulfoxide (DMSO) and 4 \times urea as eluants. Subsequently, we explored the sequential application of those eluants for differential elution of gelatinases and FN using a single affinity column. Finally, experiments characterized the stability of purified FN with or without contaminating gelatinases, as well as the effects of FN degradation on cell attachment and migration.

Results: Assay optimization demonstrated that pre-elution with 3% DMSO efficiently eliminated gelatinases but not FN from gelatin–Sepharose, whereas subsequent elution with 4 M urea released FN. Sequential elutions with DMSO and urea produced gelatinase-free FN, which was more stable than FN eluted by urea only. Fibronectin degradation did not affect human gingival fibroblast attachment, but increased cell migration significantly.

Conclusion: The present experiments devised a time- and cost-efficient protocol for eliminating gelatinases during purification of human plasma FN. Gelatinase-free FN preparations had greater stability, which may be essential for experiments because FN fragments have altered biological activities compared with intact FN.

Fibronectin (FN) is a dimeric glycoprotein (~ 440 kDa) present in plasma and other body fluids, in extracellular matrix fibrils and on cell membranes. Native FN and alternative splice forms of FN contribute to biological functions, such as cell-cell and cell-matrix interactions in wound healing, metastasis and tissue remodeling (1,2), and FN is widely used for biological experiments.

Fibronectin was initially identified as a serum factor which supported cell adhesion and bound collagen (3). doi:10.1111/j.1600-0765.2009.01241.x

© 2009 The Authors. Journal compilation © 2009 Blackwell Munksgaard

JOURNAL OF PERIODONTAL RESEARCH

S. Pal, Z. Chen, X. Xu, M. Mikhailova, B. Steffensen

Departments of Periodontics and Biochemistry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Dr Bjorn Steffensen DDS, MS, PhD, Departments of Periodontics and Biochemistry MSC 7894, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio 78229-3900, TX, USA Tel: +210 567 3564 Fax: +210 567 6858 e-mail: steffensenb@uthscsa.edu

Key words: fibronectin purification; gelatinase; human gingival fibroblast; dimethyl sulfoxide; cell attachment; cell migration

Accepted for publication June 1, 2009

Therefore, FN is commonly purified from human plasma, which contains $\sim 300 \ \mu\text{g/mL}$ FN, by gelatin (denatured type I collagen) affinity chromatography and elution with urea (4). However, FN purified by this approach contains gelatinolytic enzymes, including matrix metalloproteinases (MMPs)-2 and -9 (5). Additional steps, such as diethylaminoethyl cellulose ion exchange (6), gel filtration (5), metal affinity (7), heparin–cellufine (8) or arginine affinity chromatography (9) can separate FN from gelatinolytic enzymes, but significantly increase labor, cost and sample handling and reduce final yields.

To prevent FN degradation by co-purified enzymes, investigators have added protease inhibitors, including ethylenediaminetetraacetic acid (EDTA), phenylmethylsulfonyl fluoride (PMSF) and ϵ -amino caproic acid (10). However, such inhibitors may adversely affect cells in culture. Therefore, the development of efficient methods to purify gelatinase-free biologically active FN remains essential for investigation of the biological functions of FN and to prevent confounding effects from proteolytically generated FN fragments. Evidence for FN degradation in periodontal disease and diabetic wounds (11-13), as well as altered cell behavior on isolated FN fragments (12,14), have emphasized the importance of this issue.

Matrix metalloproteinases-2 and -9 have been purified by gelatin-affinity chromatography using dimethyl sulfoxide (DMSO) elution (15), and research performed in our laboratory demonstrated that 2% DMSO disrupts MMP-2 interactions with gelatin (16,17). Therefore, it was our working hypothesis that DMSO in this concentration range could differentially elute gelatinolytic activities but not FN bound to gelatinase-Sepharose.

Material and methods

To test purification conditions, we used analytical mini affinity columns (total bed volume, V_t 50 µL) packed with gelatin–SepharoseTM 4B (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) as detailed previously (17). Plasma was diluted fourfold with chromatography buffer (50 mM Tris– HCl, 150 mM NaCl, pH 7.4) and centrifuged at 2500g for 20 min to sediment particulate matter. Equal aliquots (500 µL) of plasma supernatant were then loaded on the analytical columns. Unbound and non-specifically bound plasma proteins were removed by extensive rinses with loading buffer $(10 \times V_t)$ and 1 M NaCl in chromatography buffer $(10 \times V_t)$. We tested elution with a concentration range of DMSO [1–7% (v/v)] in chromatography buffer $(10 \times V_t)$, 4 M urea in chromatography buffer $(3 \times V_t)$ and citrate buffer (pH 5.5) (18).

To understand to what extent DMSO and urea differentially eluted gelatinases and FN from the analytical gelatin-Sepharose columns, fractions were analyzed by the highly sensitive gelatin substrate enzymography as detailed previously (17). Briefly, samples were separated by SDS-PAGE under nonreducing conditions using 10% minislab gels co-polymerized with 150 µg/mL heat-denatured type I collagen prepared from rat tails. Gels were then washed in 5% Triton X-100, equilibrated with collagenase assay buffer (50 mm Tris, 200 mm NaCl, 5 mm CaCl₂, 0.05% Brij 35 (polyoxyethyl eneglycol dodecyl ether; Sigma, St Louis, MO, USA), 0.02% NaN₃, pH 7.4), and incubated at 37°C for 16 h. Counterstaining with Coomassie Brilliant Blue R-250 revealed enzyme activities as cleared bands against a blue background. Relative amounts of FN in fractions were quantified from digitized gel images using the ChemiDoc XRS imaging system and QUANTITY ONE[®] software version 4.5 (Bio-Rad Laboratories, Hercules, CA, USA).

Results

Fractions eluted with urea only contained both FN and high levels of gelatinolytic activities corresponding primarily to MMP-2 and -9 (not shown). However, the contaminating gelatinolytic activities could be eluted with DMSO, thereby eliminating the enzymes from the final urea fractions (Fig. 1). Increasing concentrations of DMSO more efficiently eluted the gelatinases, but decreased the recovery of FN in the final urea fractions from 63 to 41% over the concentration range of 1-7% DMSO. Among a series of concentrations and elution volumes, 6-10 bed volumes of 3% DMSO was optimal for eliminating detectable gelatinase activities from the gelatin-Sepharose columns while providing the highest recovery of gelatinase-free FN. It is plausible, but not demonstrated here, that additional proteins and proteases interacting with gelatin and FN were also eluted by DMSO.



Fig. 1. Purification of gelatinase-free human plasma fibronectin (FN) by gelatin affinity chromatography and sequential DMSO and urea elution. Diluted human plasma was centrifuged to eliminate aggregates, and a 500 µL sample was loaded on an analytical gelatin–Sepharose mini column (V_t 50 µL). Fractions representing loaded plasma (B), unbound protein (U), washes with chromatography buffer alone (W) or containing 1 \bowtie NaCl (N), equilibration with chromatography buffer (E), pre-elution with 3% DMSO (DMSO, $2-10 \times V_t$) and final elution with 4 \bowtie urea (Urea; 1–3) were analyzed by gelatin enzymography. This purification strategy produced gelatinase-free FN. Relative molecular masses (M_r) and positions corresponding to FN and MMP-2 and -9 are indicated.

The sequential DMSO-urea purification protocol was applied to a larger scale gelatin–Sepharose column ($V_{\rm t}$ 15 mL). A total of 50 mL human plasma diluted to 200 mL in chromatography buffer and sedimented as described above was loaded on the column and washed with $10 \times V_t$ each of loading buffer alone or containing 1 M NaCl. After pre-elution with $10 \times V_t$ of 3% DMSO, final elution consisted of $3 \times V_t$ of 4 M urea in chromatography buffer. Analyses by enzymography revealed a pattern of gelatinase and FN elution corresponding to that observed with analytical mini affinity columns. Final elution with 4 M urea yielded in excess of 5 mg gelatinase-free purified FN (not shown).

The stability of FN purified with and without DMSO pre-elution of gelatinases was tested by incubation at 0, 4, 22 or 37°C for 1–7 d. Fibronectin fragmentation was substantial in preparations obtained by urea elution only, but significantly less after sequential DMSO–urea elution, suggesting that the elimination of gelatinases from FN by pre-elution with DMSO enhanced the storage stability (Fig. 2; 24 h at 22°C is shown). Subsequent analysis of the biological activities of the two



Fig. 2. Stability of gelatinase-free FN. Human plasma FN purified by gelatin affinity chromatography and sequential DMSO– urea elution (+DMSO) or urea elution only (-DMSO) were incubated at 22°C for 24 h and analyzed for protein stability by 7.5% SDS-PAGE under non-reducing (-DTT) and reducing conditions (+DTT). Elimination of the gelatinolytic activities enhanced the stability of FN.



Fig. 3. Biological activities of gelatinase-free human plasma FN. Fragmented FN (FN-Fr) from urea elution and intact gelatinase-free FN from sequential DMSO–urea elution (FN; see also Fig. 2) were compared in cell-based assays. Fibronectin fragmentation did not alter cell attachment (A) but significantly increased cell migration (B). Asterisk denotes statistically significant difference (p < 0.05).

preparations in cell attachment and migration assays on protein-coated surfaces was as detailed previously (17). In brief, 40,000 human gingival fibroblasts were added per well in 96 microwell plates coated with FN preparations obtained using the urea-only or sequential DMSO-urea elution. Cells attached after 90 min were fixed, stained, and quantified by optical density after dissolution of the cell-bound stain. Cell migration assays measured the expansion on similarly coated surfaces of identical numbers of cells allowed to attach in standard-sized wells over 3 d in 0.25% serum-containing medium. Expansion was measured from digitized images of fixed and stained cell areas (12). Cell attachment assays revealed that ~3 nM FN purified by either of the two strategies was required to support half-maximal attachment of human gingival fibroblasts (Fig. 3A). In comparison, cells demonstrated significantly less migration (p < 0.05) on surfaces that were coated with sequentially DMSO-urea eluted FN (Fig. 3B) compared with urea-only eluted FN, which also displayed more FN fragmentation (see Fig. 2). Overall, these cell experiments point to a significant impact of the mode of FN purification on biological activities.

Discussion

By virtue of its high efficiency, 4 M urea has been the most commonly used

eluting agent for purification of FN by gelatin-Sepharose affinity chromatography (8,10). In our experiments, DMSO up to a concentration of 7% eluted a proportion, but not all FN bound on the columns. The choice of elution strategy should take into consideration the intended use of the purified FN. If preserving an intact conformation and functional is important, mild eluting agents, such as low-pH citric acid buffer (pH range 5.5-6.0), arginine, KBr, 1 м NaBr (1) or DMSO, may be advantageous. Strong chaotropic agents, such as urea, guanidine hydrochloride and lithium di-iodosalicylic acid, efficiently elute FN from affinity media, but may affect the structure and function of FN. For example, lithium di-iodosalicylic acid is 20-fold more efficient for FN elution than even 8 м urea in 0.1 м citric acid, pH 4.7, but the eluted FN has significantly reduced activity in cell attachment assays (19). Furthermore, urea can induce conformational changes and expose protease-sensitive sites in FN (20), which may be subject to cleavage by gelatinases, such as MMP-2 and -9, that have proteolytic activity on FN (21).

Since it had not been established whether these eluants separate gelatinases from FN, we tested and demonstrated that the commonly used low-pH eluant citric acid, pH 5.5, released gelatinases and FN from gelatin columns in the same fractions (not shown), apparently resulting from the closeness in isoelectric points for these molecules (5.39, 5.70 and 5.31, respectively). In comparison, the utility of DMSO for differential elution is consistent with reports that gelatin binding by these molecules is primarily hydrophobic in nature (22). Dimethyl sulfoxide at concentrations below 10% exerts little or no denaturing effect on lysozyme (23) and creatine kinase (24).

An intriguing question raised, but not resolved by the present series of experiments, is whether different eluants release different FN isoforms. For example, different site-specific glycopeptides of FN have been identified in plasma and cellular FN by hydrophilic affinity approaches that take advantage of the hydrogen bonding between carbohydrates of the glycopeptides in carbohydrate-based gels, such as cellulose or related substrates (25). Our experiments point to heterogeneity in gelatin binding of what could represent different forms of FN resulting from alternative splicing or differences in glycosylation.

In summary, our experiments have demonstrated that co-purified gelatinases may alter both the stability and the biological functions of FN preparation. To address this problem, we here present a time- and cost-efficient procedure for purification of gelatinase-free FN that may be applied in most laboratories to purify FN for use in biological and biochemical experiments.

Acknowledgements

We gratefully acknowledge experimental advice from Dr Robert J. Klebe, University of Texas Health Science Center at San Antonio, TX, USA. This work was supported by grants DE017139, DE 016312 and DE018135 from the National Institutes of Health.

References

- Hynes RO. *Fibronectins*. New York: Springer-Verlag, 1990.
- Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. *Int J Cancer* 2006;**118**:1331–1339.
- Klebe RJ. Isolation of a collagen-dependent cell attachment factor. *Nature* 1974; 250:248–251.
- Engvall E, Roushlahti E. Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. *Int J Cancer* 1977; 20:1–5.
- Johansson S, Smedsrod B. Identification of a plasma gelatinase in preparations of fibronectin. J Biol Chem 1986;261:4363– 4366.
- Aggeler J, Engvall E, Werb Z. An irreversible tissue inhibitor of collagenase in human amniotic fluid: characterization and separation from fibronectin. *Biochem Biophys Res Commun* 1981;100:1195– 1201.
- Smilenov L, Forsberg E, Zeligman I, Sparrman M, Johansson S. Separation of Fibronectin from A Plasma Gelatinase Using Immobilized Metal Affinity-Chromatography. *FEBS Lett* 1992;**302:**227– 230.
- Poulouin L, Gallet O, Rouahi M, Imhoff JM. Plasma fibronectin: Three steps to purification and stability. *Protein Expr Purif* 1999;17:146–152.
- Speziale P, Visai L, Rindi S, Di Poto A. Purification of human plasma fibronectin using immobilized gelatin and Arg affinity chromatography. *Nat Protoc* 2008;3:525– 533.
- Akiyama SK. Purification of Fibronectin. In: Bonifacino JS, Dasso M, Harford JB, Lippincott-Schwartz J, Yamada KM, eds. *Current Protocols in Cell Biology*. Indianapolis: John Wiley & Sons Inc, 2001: 10.5.1–10.5.13.
- Talonpoika J, Heino J, Larjava H, Hakkinen L, Paunio K. Gingival crevicular fluid fibronectin degradation in periodontal health and disease. *Scand J Dent Res* 1989;97:415–421.
- Stanley CM, Wang Y, Pal S et al. Fibronectin fragmentation is a feature of periodontal disease sites and diabetic foot and leg wounds and modifies cell behavior. J Periodontol 2008;79:861–875.
- Huynh QN, Wang S, Tafolla E et al. Specific fibronectin fragments as markers of periodontal disease status. J Periodontol 2002;73:1101–1110.

- Clark RA, An JQ, Greiling D, Khan A, Schwarzbauer JE. Fibroblast migration on fibronectin requires three distinct functional domains. *J Invest Dermatol* 2003; 121:695–705.
- Shimokawa K, Nagase H. Purification of MMPs and TIMPs. In: Ian M, ed. *Matrix Metalloproteinase Protocol*. Totowa: Humana Press, 2001:275–304.
- 16. Xu X, Wang Y, Lauer-Fields JL, Fields GB, Steffensen B. Contributions of the MMP-2 collagen binding domain to gelatin cleavage - Substrate binding via the collagen binding domain is required for hydrolysis of gelatin but not short peptides. *Matrix Biol* 2004;23:171–181.
- Steffensen B, Xu X, Martin PA, Zardeneta G. Human fibronectin and MMP-2 collagen binding domains compete for collagen binding sites and modify cellular activation of MMP-2. *Matrix Biol* 2002; 21:399–414.
- Miekka S, Ingham K, Menache D. Rapid methods for isolation of human plasma fibronectin. *Thromb Res* 1989;27:1–14.
- Klebe RJ, Bentley KL, Sasser PJ, Schoen RC. Elution of fibronectin from collagen with chaotrophic agents. *Exp Cell Res* 1980;130:111–117.
- Markovic Z, Lustig A, Engel J. Shape and stability of fibronectin in solutions of different pH and ionic strength. *Hoppe Seylers Z Physiol Chem* 1983;364:1795–1804.
- Steffensen B, Hakkinen L, Larjava H. Proteolytic events of wound-healing – coordinated interactions among matrix metalloproteinases (MMPs), integrins, and extracellular matrix molecules. Crit Rev Oral Biol Med 2001;12:373–398.
- Pickford AR, Smith SP, Staunton D, Boyd J, Campbell ID. The hairpin structure of the (6)F1(1)F2(2)F2 fragment from human fibronectin enhances gelatin binding. *EMBO J* 2001;20:1519–1529.
- Bhattacharjya S, Balaram P. Effects of organic solvents on protein structures: observation of a structured helical core in hen egg-white lysozyme in aqueous dimethylsulfoxide. *Proteins* 1997;29:492–507.
- Ou WB, Park YD, Zhou HM. Effect of osmolytes as folding aids on creatine kinase refolding pathway. *Int J Biochem Cell Biol* 2002;34:136–147.
- Tajiri M, Yoshida S, Wada Y. Differential analysis of site-specific glycans on plasma and cellular fibronectins: application of a hydrophilic affinity method for glycopeptide enrichment. *Glycobiology* 2005; 15:1332–1340.

This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.